[Abiraterone plus prednisone in patients with newly diagnosed high-risk metastatic hormone-sensitive prostate cancer (mHSPC)].

The most exciting data presented at the 2017 ASCO Annual Meeting included the results of the LATITUDE and STAMPEDE trials, which evaluated abiraterone plus prednisone combined with androgen-deprivation therapy (ADT) as a first-line treatment in men with newly diagnosed high-risk metastatic hormone-sensitive prostate cancer (mHSPC), demonstrating a practice-changing alternative to chemo-hormonal treatment with docetaxel plus ADT. In both trials, the addition of abiraterone plus prednisone to ADT significantly prolonged both progression-free survival and overall survival. In the absence of head-to-head evidence, it remains unclear if abiraterone plus prednisone and ADT should be the new gold standard for patients with newly diagnosed high-risk mHSPC. However, the results of indirect comparisons demonstrate that abiraterone plus prednisone is similarly or even more effective compared with chemotherapy and better tolerated overall.